Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

This early phase I trial studies the possible benefits and/or side effects of topical or oral minoxidil in treating endocrine therapy-induced hair loss (alopecia) in patients with stage I-IV breast cancer. Endocrine therapy-induced alopecia (EIA) is a distressing side effect that leads to reduced quality of life and early cessation of therapy in women undergoing treatment for breast cancer. Patients on endocrine therapy commonly report hair loss or thinning. Minoxidil is a drug that may promote hair growth and reduce hair loss. Oral minoxidil may increase hair density in women with EIA, and wo

Trial Details

NCT ID
NCT05417308
Phase
EARLY_PHASE1
Sponsor
Ohio State University Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Minoxidil
  • Quality-of-Life Assessment
  • Questionnaire Administration
Locations (sample)
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Women \>= 18 years of age
  • Established diagnosis of breast cancer stages I-IV
  • On endocrine therapy including tamoxifen or aromatase inhibitors with or without concurrent use of ovarian function suppression
  • Self-reporting hair loss since starting endocrine therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →